Abstract
The study covers the issues like: understanding the structure, growth, characteristics and current issues of Indian pharmaceutical industry; How drug manufacturers have been coping with TRIPS Regulations (post 2005) in India like ‘product patents’ and what threats and opportunities they are visualizing in future?; The ‘product patent’ implications on Pharmaceutical Industry on issues like its influence on mergers/acquisitions, labour issues (skilled labour attrition) and RD and its probable effect (as expressed by manufacturers) on public health and drug pricing are dicussed. There is a clear difference in the impact of the TRIPs on size of the firms. Small and medium scale firms having less capacity to invest in R&D are concentrating on Bulk Drug production and export market by improving the quality of deliverables. Whereas the Large scale firms feel the need to expand the R&D investment and collaborate with foreign firms to survive in the market. Most of the large firms are also involved in strategic Mergers and Takeovers and at the same time they are also threatened by the fear of being taken over. However there is a long way to travel for our Indian Pharma Companies to become leaders in Global Pharmaceuticals as the R&D investment is yet to match the global standards.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
